Processa Pharmaceuticals annual capital expenditures (capex)
2012
2013
2014
2015
2016
2017
2018
2023
2024
2025
Processa Pharmaceuticals Capital Expenditures (CapEx) Growth & History (PCSA)
Processa Pharmaceuticals's capital expenditures (capex) was $850,000 for fiscal 2025.
View full Processa Pharmaceuticals company overviewProcessa Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $850,000 | $846,756 | +26102.22% |
| 2024 | 2024-12-31 | $3,244 | $468 | +16.86% |
| 2023 | 2023-12-31 | $2,776 | — | — |
| 2018 | 2018-12-31 | $22,282 | $1,660 | +8.05% |
| 2017 | 2017-12-31 | $20,622 | −$3,153 | −13.26% |
| 2016 | 2016-12-31 | $23,775 | $22,376 | +1599.43% |
| 2015 | 2015-12-31 | $1,399 | −$9,608 | −87.29% |
| 2014 | 2014-12-31 | $11,007 | −$16,667 | −60.23% |
| 2013 | 2013-12-31 | $27,674 | −$306,664 | −91.72% |
| 2012 | 2012-12-31 | $334,338 | — | — |
Processa Pharmaceuticals quarterly capital expenditures (capex)
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.17
Q2.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2018 | 2018-12-31 | $20,500 | — | — |
| Q3 2018 | 2018-09-30 | $0 | — | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q1 2018 | 2018-03-31 | $1,782 | $900 | +102.04% |
| Q2 2017 | 2017-06-30 | $0 | — | — |
| Q1 2017 | 2017-03-31 | $882 | — | — |
| Q4 2015 | 2015-12-31 | $0 | −$14,712 | — |
| Q3 2015 | 2015-09-30 | $0 | −$9,947 | — |
| Q2 2015 | 2015-06-30 | $0 | −$2,000 | — |
| Q1 2015 | 2015-03-31 | $1,399 | −$12,373 | −89.84% |
| Q4 2014 | 2014-12-31 | $14,712 | $14,711 | +1471100.00% |
| Q3 2014 | 2014-09-30 | $9,947 | −$10,394 | −51.10% |
| Q2 2014 | 2014-06-30 | $2,000 | $944 | +89.39% |
| Q1 2014 | 2014-03-31 | $13,772 | $7,496 | +119.44% |
| Q4 2013 | 2013-12-31 | $1 | — | — |
| Q3 2013 | 2013-09-30 | $20,341 | −$223,932 | −91.67% |
| Q2 2013 | 2013-06-30 | $1,056 | — | — |
| Q1 2013 | 2013-03-31 | $6,276 | — | — |
| Q3 2012 | 2012-09-30 | $244,273 | — | — |
Processa Pharmaceuticals capital expenditures (capex) trends
Between the periods ended 2012-12-31 and 2025-12-31, Processa Pharmaceuticals's capital expenditures (capex) increased from $334,338 to $850,000, a change of $515,662. The latest reported quarter, Q4 2018, shows $20,500.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Processa Pharmaceuticals source filings ↗